文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

18F-Fluciclovine PET/CT对前列腺癌根治术后生化复发拟行挽救放疗患者管理的影响:LOCATE研究

18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE.
PubMed 文献 · Pract Radiat Oncol · 2020-05-25

LOCATE研究的事后亚组分析纳入114例根治术后生化复发、常规影像阴性或不确定、计划行挽救放疗的前列腺癌患者,18F-Fluciclovine PET/CT在42%患者中阳性,48%患者管理改变,32%改变整体治疗策略。PSA>0.5 ng/mL和Gleason评分≥8与盆腔外阳性风险升高相关。

要点

  • 18F-Fluciclovine PET/CT在拟行挽救放疗的根治术后生化复发患者中阳性率42%。
  • 48%患者PET/CT后管理改变,32%改变整体治疗策略(如省略挽救放疗)。
  • PSA>0.5 ng/mL和GS≥8与盆腔外阳性风险升高相关(P<.05)。

核心结论

  • 对于根治术后生化复发、常规影像阴性或不确定、计划行挽救放疗的前列腺癌患者,18F-Fluciclovine PET/CT在近半数患者中阳性,且常导致管理改变。
  • PSA>0.5 ng/mL和GS≥8与盆腔外阳性风险升高相关。

研究设计与样本

  • LOCATE(NCT02680041)为前瞻性多中心研究,本分析为其亚组分析,纳入114例根治术后生化复发、常规影像阴性或不确定、计划行挽救放疗(±激素治疗)的患者。
  • 患者行18F-Fluciclovine PET/CT,比较扫描前后治疗计划,采用Fisher精确检验分析扫描前PSA和GS对阳性及解剖摄取模式的影响。

主要发现

  • 114例患者中48例(42%)存在18F-Fluciclovine摄取病灶。
  • 扫描后55例(48%)管理改变,其中37例(32%)整体治疗策略改变(如省略挽救放疗),18例(16%)挽救放疗靶区修改。
  • 扫描前PSA中位值0.42 ng/mL(四分位距0.3-1.1)。

关键数值与推荐

  • PSA>0.5 ng/mL和GS≥8与盆腔外阳性风险升高相关(P<.05)。

临床怎么用

  • 对根治术后生化复发、常规影像阴性或不确定、计划行挽救放疗的患者,可考虑行18F-Fluciclovine PET/CT以指导治疗决策。
  • PSA>0.5 ng/mL或GS≥8的患者盆腔外阳性风险较高,PET/CT结果可能影响挽救放疗靶区或整体策略。

局限性

  • 本分析为LOCATE研究的亚组分析,样本量114例。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Conventional imaging rarely localizes the site(s) of prostate cancer recurrence in patients undergoing evaluation for salvage radiation therapy (sRT) after radical prostatectomy (RP). LOCATE (NCT02680041) was a prospective, multicenter study investigating the impact of 18F-fluciclovine positron emission tomography and computed tomography (PET/CT) on the management of patients with biochemical recurrence of prostate cancer after curative-intent radiation or RP and negative or equivocal conventional imaging. Our objective was to determine the impact of 18F-fluciclovine PET/CT on treatment decisions for men planning to undergo sRT for biochemical recurrence post-RP. METHODS AND MATERIALS: We conducted a subgroup analysis of post-RP patients enrolled in LOCATE who were planning to undergo sRT with or without hormonal therapy based on prescan documentation. 18F-Fluciclovine PET/CT was performed according to standardized procedures. The treatment plan postscan was compared with the prescan plan, and Fisher exact test was used to determine the impact of prescan prostate-specific antigen (PSA) and Gleason sum (GS) on positivity and anatomic patterns of uptake. RESULTS: A total of 114 patients (median prescan PSA 0.42 [interquartile range, 0.3-1.1] ng/mL) met selection criteria (54% of patients in LOCATE). Forty-eight (42%) had 18F-fluciclovine-avid lesions. Twelve patients (11%) had positive findings only in the prostate bed, 24 (21%) had positivity only in the pelvis (prostate bed or pelvic nodes), and 24 (21%) had extrapelvic findings. PSA >0.5 ng/mL and GS ≥8 were associated with a higher risk of extrapelvic positivity (P < .05). Postscan, 55 (48%) patients had a management change; 37 (32%) had a change in overall treatment approach (ie, omission of sRT); and 18 (16%) had sRT target modification. CONCLUSIONS: 18F-Fluciclovine PET/CT is positive in nearly half of patients planning to undergo post-RP sRT with negative/equivocal conventional imaging, with findings frequently leading to changes in management. PSA >0.5 ng/mL and GS ≥8 are associated with a higher risk of extrapelvic positive findings.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Solanki AA, Savir-Baruch B, Liauw SL, et al. 18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE. Pract Radiat Oncol. 2020. PMID: 32464368. doi:10.1016/j.prro.2020.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。